Similarly, with respect to other stroke subtype outcomes, subgroup analysis indicated that SGLT2 inhibition had no significant effect on either fatal (RR = 0.87, 95% CI 0.60–1.27, P = 0.482; Fig. 2B) or non-fatal stroke (RR = 0.98, 95% CI 0.86–1.11, P = 0.767; Fig. 2A). This evidence concerns the gene SLC5A2 and stroke disorder.